Contents

Issue 143 • June 2024

In association with

Cover Story

Lula’s progress plan for Brazil: a year on

Feature

Tracking the opioid lawsuit settlements amidst calls for oversight

Interview

Cell and gene therapy value assessments need a rework to allow access

In Depth

Lula’s progress plan for Brazil: A year on

How sham patents are hurting the pharma industry

Tracking the opioid lawsuit settlements amidst calls for oversight

Cell and gene therapy landscape in the US

Q&A: Cell and gene therapy value assessments need a rework to allow access

Q&A: Pharmaceutical discovery through a gravitational lens

Briefing

News in Numbers

Latest News

Latest Deals

Project Updates

Trends & Insight

In Data

M&A activity in the mining industry

Hiring activity in the mining industry decreased

Patent activity in the mining industry decreased

Sentiment in the mining industry increased

Thematic Take

ESG in the pharma sector

Powered by

06/04/2024 13:18:50
  • Home | Lula’s progress plan for Brazil: A year on
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Xylem
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Project Updates
  • Trends & Insight
  • phasetwo
  • Datwyler Company Insight
  • Datwyler
  • In Depth
  • Lula’s progress plan for Brazil: A year on
  • How sham patents are hurting the pharma industry
  • Tracking the opioid lawsuit settlements amidst calls for oversight
  • Cell and gene therapy landscape in the US
  • Q&A: Cell and gene therapy value assessments need a rework to allow access
  • Pharmaceutical discovery through a gravitational lens
  • Thematic Take: ESG
  • Thematic Take: contents
  • Foreword: A growing sense of urgency in ESG
  • ESG 1.0 is over – get ready for ESG 2.0
  • ESG becomes mandatory: how to prepare
  • Theme timeline: the past, present and future of ESG
  • Net-zero strategies for the pharma sector
  • Leading pharma companies and initiatives in the race for net zero
  • GlobalData’s Christopher Papadopoullos on net-zero strategy for businesses
  • 38% of companies lack an ESG strategy – GlobalData survey
  • Sustainability challenges in rare disease trials remain, but change is happening
  • ESCMID 2024: The infectious consequences of climate change
  • Bring your own device: How patients own tech is being used in clinical trials
  • Can pharma overcome generative AI’s bias problem?
  • China-US tensions are spilling into the biotech sector
  • Japanese patients among least empowered in the developed world
  • World Air Quality Report: what are the health impacts and where is it worst?
  • Why has New Zealand U-turned on the world’s first smoking ban?
  • Microplastics in placentas: how serious is the problem?
  • Deal activity related to ESG in the pharma industry since 2021
  • GlobalData Thematic Intelligence
  • Sponsored Supplements
  • BEA Technologies
  • Cytiva
  • Listings
  • Events
  • Innovation Rankings
  • Buyer's Guides
  • Next issue
05/22/2024 00:00:00